Thursday, July 21, 2022
Wellbeing Digital Sciences Inc., a mental healthcare company focusing on evidence-based clinical solutions, including psychedelic medicine and digital therapeutics, has announced that its subsidiary, KGK Sciences Inc., has entered into a research services agreement with Halucenex Life Sciences Inc., a psychedelic subsidiary of Creso Pharma.
The collaboration aims to conduct phase II clinical trials to assess the efficacy of psilocybin in treating treatment-resistant Post Traumatic Stress Disorder (PTSD). The research services agreement will involve KGK performing various tasks, including the development of the clinical trial protocol, preparation for the Phase II trials, data management and validation, statistical analysis, and drafting the final report.
Najla Guthrie, CEO of Wellbeing and KGK, expressed enthusiasm for working with Halucenex on this important step toward creating alternative medicines for a growing population in need. With over 25 years of experience in designing clinical trials and substantiating product claims, KGK is well-positioned to support the advancement of the psychedelic industry.
Bill Flemming, CEO and Founder of Halucenex, highlighted KGK's expertise as a leading contract research organization (CRO) in providing high-quality clinical research trials and regulatory support for the nutraceutical, cannabinoid, hemp, and psychedelic industries. Flemming expressed confidence that KGK's involvement would contribute to significant progress in developing alternative treatment solutions to current pharmacological interventions.
This collaboration represents a significant move in advancing the field of psychedelic medicine and exploring its potential as a therapeutic option for individuals with treatment-resistant PTSD
